Salute e Benessere

Sandoz reports second-quarter sales and half-year 2024 results

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASEStrong double-digit growth in biosimilars of 29% from existing portfolio and recent launches Second-quarter net sales[1] of USD 2.6 billion, up 9% in constant currencies (up 7% in USD)Half-year net sales of USD 5.0 billion, up 7% in constant currencies (up 6% in USD)Half-year core EBITDA margin[2] of 17.5%, a strong 210 basis point improvement versus H2 2023, driven by favorable biosimilars mix;...
Nasdaq GlobeNewswire
08/08/2024

Bavarian Nordic Receives USD 156.8 Million from the U.S. Government for…

The contract will help replenish inventory of bulk vaccine required for future manufacturing and supply of freeze-dried vaccines.COPENHAGEN, Denmark, August 8, 2024– Bavarian Nordic A/S (OMX: BAVA) today announced that it has received a new order valued at USD 156.8 million from the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services, to manufacture...
Nasdaq GlobeNewswire
08/08/2024

WestGene to Advance Clinical Trials Following Dual IND Approvals for World's…

On 6 August, the Center for Drug Evaluation (CDE) of the NMPA approved the clinical trial application for WGc-043 injection, allowing the initiation of Phase I clinical trials. This dual approval further validates WestGene's expertise in core mRNA technologies such as delivery vectors and sequence design, and accelerates the commercialisation of effective and low-toxicity anti-tumour mRNA vaccines worldwide. On 6 August, the Center for Drug Evaluation (CDE) of the NMPA approved the clinical...
PR Newswire
08/08/2024

LG UNVEILS NEW THERMA V™ R290 MONOBLOC MODELS WITH ADVANCED COMPRESSOR AT IFA…

With the mandatory implementation of Nearly-Zero Energy Buildings (NZEB) standards across Europe,1 AWHPs are gaining popularity for their ability to reduce carbon emissions and handle energy supply uncertainties. For new constructions, medium- and small-capacity models are more suitable, making LG's new 7- and 9 kW models ideal for the European market. Additionally, LG is establishing an Air Solution Research and Development (R&D) Lab in Frankfurt, Germany, to develop high-efficiency…
PR Newswire
08/08/2024

Novartis receives FDA accelerated approval for Fabhalta® (iptacopan), the first…

Ad hoc announcement pursuant to Art. 53 LR Fabhalta achieved a 44% proteinuria reduction from baseline in Phase III APPLAUSE-IgAN interim analysis, compared with 9% in placebo arm, demonstrating a clinically meaningful reduction of 38% vs. placebo (p<0.0001) 1Fabhalta is an inhibitor of the alternative complement pathway, activation of which is thought to contribute to the pathogenesis of IgAN 1-4Despite current standard of care, up to 50% of IgAN patients with persistent...
Nasdaq GlobeNewswire
08/08/2024

Endo to Host Investor Call on Second Quarter 2024 Financial Results

A replay of the webcast will be available within 24 hours at investor.endo.com. A replay of the webcast will be available within 24 hours atinvestor.endo.com. About EndoEndo is a diversified specialty pharmaceutical company boldly transforming insights into life-enhancing therapies. Our passionate team members collaborate to develop and deliver these essential medicines. Together, we are committed to helping everyone we serve live their best life. Learn more atwww.endo.comor...
PR Newswire
07/08/2024

Fierce Competition and Technological Innovation Drive Diabetes Care Devices…

As awareness around diabetes increases, so do diagnosis rates. Global screening tests for early detection of T2D in adults have shown significant sensitivity and specificity, leading to higher diagnosis rates and, consequently, greater demand for diabetes care devices. As awareness around diabetes increases, so do diagnosis rates. Global screening tests for early detection of T2D in adults have shown significant sensitivity and specificity, leading to higher diagnosis rates and, consequently,...
PR Newswire
07/08/2024

PeproMene Bio announced study demonstrating strong polyfunctionality of novel…

Researchers used a single-cell platform, which found that PMB-CT01 CAR T cells, had more polyfunctionality, which is T cells' ability to perform several functions at the same time, than CD 19 CAR T cells. PMB-CT01 cells also produced more stimulatory cytokines, which can spur the immune system, and effector cytokines, which can directly kill cancer cells. Researchers used a single-cell platform, which found that PMB-CT01 CAR T cells, had more polyfunctionality, which is T cells' ability to...
PR Newswire
07/08/2024

Glucose Monitoring Devices Market to Reach $38.9 Billion, Globally, by 2033 at…

Request Sample of the Report on Glucose Monitoring Devices Market Forecast 2033 - https://www.alliedmarketresearch.com/request-sample/A62953 Request Sample of the Report on Glucose Monitoring Devices Market Forecast 2033 -https://www.alliedmarketresearch.com/request-sample/A62953 Prime determinants of growth Rise in incidences of diabetes, favorable regulatory scenario, and growing awareness regarding the availability of various glucose monitoring devices are the major factors...
PR Newswire
07/08/2024

In Vitro Fertilization Market worth $1,650 million by 2029 driven by…

Browse in-depth TOC on "In Vitro Fertilization Market" Browse in-depth TOC on "In Vitro Fertilization Market" 249 - Tables52 - Figures280 - Pages CooperSurgical Inc.: Comprehensive Leader in IVF Solutions CooperSurgical Inc., based in the US, is a leading provider of a wide range of products and services for reproductive health professionals. Their extensive portfolio includes advanced equipment and technologies crucial for all phases of in vitro fertilization (IVF),...
PR Newswire
07/08/2024

Forensic Equipment and Supplies Market to Reach $16.5 Billion, Globally, by 2033…

Request Sample of the Report on Forensic Equipment and Supplies Market Forecast 2033 - https://www.alliedmarketresearch.com/request-sample/A09493 Request Sample of the Report on Forensic Equipment and Supplies Market Forecast 2033 -https://www.alliedmarketresearch.com/request-sample/A09493 Prime determinants of growth Increasing incidences of crime, rise in awareness and emphasis on forensic science in criminal investigations, and expanding application of forensic science are...
PR Newswire
07/08/2024

Functional Service Providers (FSP) Market 2024-2031 | Transform Your Business…

The Functional Service Providers (FSP) market is an element of the pharmaceutical and clinical research industry that provides services and resources to support various tasks in drug development and clinical trials. Clinical monitoring, statistical control, biostatistics, pharmacovigilance, scientific writing, and regulatory affairs are typical services provided by FSP groups. FSPs address a wide range of demands, including clinical operations, data administration, biostatistics, regulatory…
PR Newswire
07/08/2024

C2N Diagnostics and Unilabs Announce Global Partnership, Bringing Together…

"Alzheimer's disease is on the rise, making it essential to innovate by offering less invasive and more accessible diagnostic procedures for patients," said Unilabs' Head of Innovation Dr. Rahul Chaudhary. "All too often, diagnosing Alzheimer's has been painful, invasive and expensive. This partnership will transform the diagnostic experience for patients with cognitive concerns while revolutionizing early diagnosis, and research efforts, and positively impacting long-term…
PR Newswire
07/08/2024

Abbott Enters Global Partnership to Connect Its World-Leading Continuous Glucose…

AID systems improve health outcomes while reducing the burden of constant decision-making for people with diabetes who use intensive insulin as part of their overall therapy. AID systems can benefit people with both Type 1 and Type 2 diabetes who require multiple daily injections of rapid-acting insulin, currently estimated at more than 11 million people globally2. AID systems improve health outcomes while reducing the burden of constant decision-making for people with diabetes who use...
PR Newswire
07/08/2024

MoonLake Immunotherapeutics Reports Second Quarter 2024 Financial Results and…

MoonLake Immunotherapeutics Reports Second Quarter 2024 Financial Results and Announces a Capital Markets Update for September 11 Initiated Phase 3 VELA program of the Nanobody ®sonelokimab in hidradenitis suppurativa (“HS”), with topline results anticipated as of mid-2025Secured positive feedback from both U.S. Food and Drug Administration (“FDA”) and the E.U. European Medicines Agency (“EMA”) on the regulatory path for the Phase 3 program of the Nanobody ®sonelokimab in...
Nasdaq GlobeNewswire
07/08/2024

Ultimovacs Announces Notice of Resignation from Deputy Board Member

Oslo, August 7, 2024:Ultimovacs ASA (“Ultimovacs”) (OSE ULTI) today announced that it has received notice from deputy board member Ketil Fjerdingen that he has resigned from his position as deputy member of the Company's Board of Directors.The Company wishes to thank Ketil Fjerdingen for his service to the Company over the years.For further information, please see www.ultimovacs.com or contact: Jónas Einarsson, Chair of the Board of Directors of Ultimovacs ASAEmail:...
Nasdaq GlobeNewswire
07/08/2024

AI that Detects Hidden Heart Disease is a Finalist for British Heart…

Caristo is proud to announce that the BHF-funded project that led to the creation of the company and the development of the CaRi-Heart® AI technology, is one of the three candidates for the award. Caristo is proud to announce that the BHF-funded project that led to the creation of the company and the development of the CaRi-Heart® AI technology, is one of the three candidates for the award. TheCaRi-Hearttechnology applies advanced AI algorithms to routine heart coronary computed...
PR Newswire
07/08/2024

Suppository Packaging Market worth $428 million by 2029 - Exclusive Report by…

Browse in-depth TOC on "Suppository Packaging Market". Browse in-depth TOC on "Suppository Packaging Market". 220 – Tables 45 – Figures 240 – Pages Download PDF Brochure:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=8869604 "Aluminum/PE is the second largest material of the suppository packaging, in terms of value" Aluminum/PE material effectively minimizes the risk of suppositories from moisture, oxygen, light and other factors leading to...
PR Newswire
07/08/2024

Global Retail Industry - Insights around Market Size, Key Trends and Forecast…

The global athleisure market size was USD 358.07 billion in 2023 and is projected to grow at a CAGR of 9.3% from 2024 to 2030. The growing enthusiasm for sports and outdoor recreational activities among the young population is expected to drive the demand for athleisure. A key factor contributing to this trend is the increasing awareness of fitness and health, boosting the need for comfortable and stylish clothing. The global athleisure market size wasUSD 358.07 billionin 2023 and is...
PR Newswire
07/08/2024

Photocure ASA: Results for the second quarter of 2024

Photocure reported total group revenues of NOK 145.4 million in the second quarter of 2024 (NOK 144.3 million), and EBITDA* of NOK 27.8 million (NOK 23.4 million), driven by revenue growth and a milestone payment from Asieris for the NDA acceptance of Cevira® in China. Hexvix/Cysview revenues were NOK 122.4 million in the quarter (Q2 2023: NOK 115.9 million). The EBIT was NOK 20.7 million (NOK 16.8 million) and the cash balance at the end of the period was NOK 267.0 million. Photocure…
PR Newswire
07/08/2024

Cellectis Appoints Dr. Adrian Kilcoyne as Chief Medical Officer

“We're thrilled to welcome Dr. Kilcoyne to Cellectis. He is a strategic, forward-thinking drug developer who is passionate about delivering life-saving therapies to patients. His clinical vision and proven leadership, as well as his extensive experience, will strengthen our clinical development efforts as we advance our product pipeline of next-generation CAR T-cell therapies,” said André Choulika, Ph.D., Chief Executive Officer at Cellectis.Before joining Cellectis, Dr. Kilcoyne was...
Nasdaq GlobeNewswire
07/08/2024

Novo Nordisk's sales increased by 24% in Danish kroner and by 25% at constant…

Bagsværd, 7 August 2024 - Financial report for the period 1 January 2024 to 30 June 2024 Operating profit increased by 18% in Danish kroner and by 19% at constant exchange rates (CER) to DKK 57.8 billion. Operating profit is impacted by the impairment loss related to ocedurenone of DKK 5.7 billion.Sales in North America Operations increased by 36% in Danish kroner (36% at CER). Sales growth in the US was positively impacted by gross-to-net sales adjustments related to prior years...
Nasdaq GlobeNewswire
07/08/2024

Cellectis Provides Financial Results for the Second Quarter 2024

ODD and RPDD granted by the FDA and ODD granted by the European Commission to UCART22 for the treatment of ALL ODD granted by the FDA to CLLS52 (alemtuzumab) for ALL treatment Cash position of $273 million as of June 30, 2024 1 ; cash runway projection into 2026 NEW YORK, Aug.06, 2024(GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving...
Nasdaq GlobeNewswire
06/08/2024

Nyxoah Reports Second Quarter and First Half 2024 Financial and Operating…

REGULATED INFORMATIONNyxoah Reports Second Quarter and First Half 2024 Financial and Operating Results FDA regulatory submission complete, U.S. approval on track for end of 2024 U.S. commercial launch fully funded with over €85 million in new capital raisedMont-Saint-Guibert, Belgium – August 6, 2024, 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of...
Nasdaq GlobeNewswire
06/08/2024
Altri  Comunicati